TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29252096

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 24
Study: 30354632

Group type: EXPERIMENTAL
Intervention: High-speed rotational atherectomy (RA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Modified balloons (MB)
Number of subjects: 200
Study: 26486011

Group type: EXPERIMENTAL
Intervention: Dydrogesterone 20 mg twice daily (n=96)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Micronized progesterone 400 mg twice daily (n=114)
Number of subjects: 210
Study: 25174150

Group type: EXPERIMENTAL
Intervention: Intervention Group (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Delayed Intervention Group (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 120
Study: 21479565

Group type: EXPERIMENTAL
Intervention: Resin sealants (60 sealants applied)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Composite restorations (12 restorations applied)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Radiographic assessment of sealed lesions
Number of subjects: 52
Study: 20647337

Group type: EXPERIMENTAL
Intervention: 200 microg/d selenium p.o. (as selenized yeast)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 800 microg/d selenium p.o. (as selenized yeast)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 800 microg selenium in men with highest quartile of baseline selenium
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 17468524

Group type: EXPERIMENTAL
Intervention: Fortified human milk
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Fortified human milk in SGA babies
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Fortified human milk in AGA babies
Number of subjects: 166

Group type: COMPARATOR
Intervention: Exclusive human milk (control)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Exclusive human milk in SGA babies (control)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Exclusive human milk in AGA babies (control)
Number of subjects: 166
Study: 15259296

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (CRO) 10 mg, administered twice in the first 24 hours postoperatively
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intravenous tramadol/metamizol (TM) 100 mg tramadol + 1 g metamizol every 4 h for 24 h, placebo tablet at recovery
Number of subjects: 35
Study: 12099518

Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion absorption profiling (AUC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional trough-level drug monitoring (C0)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclosporine exposure measured by AUC[0-12]
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclosporine exposure measured by AUC[0-4]
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclosporine exposure measured by C2 level
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: C2 values above approximately 1500 microg/L by day 3 post-transplant
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trough (C0) levels
Number of subjects: 21
Study: 10233191

Group type: EXPERIMENTAL
Intervention: PAM (pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and metronidazole 250 mg q.d.s.)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PCM (pantoprazole 40 mg o.d. plus clarithromycin 250 mg b.d. and metronidazole 250 mg q.d.s.)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PAC (pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d.)
Number of subjects: 116
Study: 7570719

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 1011
Study: 2112516

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nitroglycerin (0.8 mg)
Number of subjects: 24
Study: 623044

Group type: EXPERIMENTAL
Intervention: Amino acids alone (1 g/kg per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amino acids plus 100 g glucose daily
Number of subjects: 10
Study: 29849514

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 149

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 149
Study: 26428452

Group type: COMPARATOR
Intervention: standard CDC Tdap VIS (sVIS)
Number of subjects: 279

Group type: COMPARATOR
Intervention: modified version Tdap VIS (mVIS)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Tdap vaccine information statement (VIS)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Tdap vaccination intention (T2)
Number of subjects: 279
Study: 24026037

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Losartan and Carvedilol
Number of subjects: 182
Study: 23273339

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10000
Study: 20709992

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg tablet once daily)
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 19040336

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg, three times daily for 6 months (O group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day for 6 months (E group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg and Ezetimibe 10 mg/day for 6 months (OE group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 15867169

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin and irbesartan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11436193

Group type: EXPERIMENTAL
Intervention: MOD‐GI meal (rolled oats, moderate GI, approximately 61)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HI‐GI meal (puffed rice, high GI, approximately 82)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (water alone)
Number of subjects: 6
Study: 9493502

Group type: EXPERIMENTAL
Intervention: Caffeine at 3 mg/kg bodyweight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine at 1 mg/kg bodyweight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time of day (TOD)
Number of subjects: 0
Study: 7995662

Group type: EXPERIMENTAL
Intervention: Silent myocardial ischemia detected via 24-hour ambulatory ECG monitoring
Number of subjects: 42

Group type: COMPARATOR
Intervention: No silent myocardial ischemia
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Silent myocardial ischemia test
Number of subjects: 42
Study: 3281386

Group type: EXPERIMENTAL
Intervention: Dithranol (0.1/0.2%) plus urea (17%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Desoximetasone (0.25%)
Number of subjects: 20
Study: 1734683

Group type: EXPERIMENTAL
Intervention: Intrinsically labeled bread (45Ca injected into wheat plants)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Extrinsically labeled bread (45Ca added to flour)
Number of subjects: 11
Study: 28619

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Benorylate (6 g/day)
Number of subjects: 60
Study: 30667557

Group type: EXPERIMENTAL
Intervention: 0.6% sodium alginate (SA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: 0.4% sodium hyaluronate (SH) (control)
Number of subjects: 130
Study: 28618737

Group type: EXPERIMENTAL
Intervention: Artcure Diffusional Patch
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo transdermal diffusional patch
Number of subjects: 79
Study: 25863956

Group type: EXPERIMENTAL
Intervention: Ovsynch plus 3000 IU hCG
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ovsynch (control)
Number of subjects: 80
Study: 23584572

Group type: EXPERIMENTAL
Intervention: Gaps in airway pressure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gaps in airway flow
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gaps in tidal volume
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Disappearance gaps in tidal volume, airway pressure, and flow waveforms
Number of subjects: 50
Study: 21736531

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cholecystectomy
Number of subjects: 64
Study: 19589242

Group type: EXPERIMENTAL
Intervention: Simvastatin (6 months treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine therapy alone (control group)
Number of subjects: 76
Study: 18023644

Group type: EXPERIMENTAL
Intervention: FPCIs
Number of subjects: 247

Group type: COMPARATOR
Intervention: Toys
Number of subjects: 247
Study: 15134184

Group type: EXPERIMENTAL
Intervention: unboosted amprenavir (APV)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: P459Ins (insertions in p6 protein)
Number of subjects: 84

Group type: COMPARATOR
Intervention: wild-type (no insertions in p6 protein)
Number of subjects: 84
Study: 11784832

Group type: EXPERIMENTAL
Intervention: Detailed cognitive assessment and treatment programme
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Detailed cognitive assessment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 240
Study: 9701525

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 11

Group type: COMPARATOR
Intervention: H. pylori positive (control)
Number of subjects: 11

Group type: COMPARATOR
Intervention: H. pylori positive (uncontrolled trials)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: H. pylori negative (uncontrolled trials)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eradication regimens based on omeprazole plus antibiotics and bismuth plus antibiotics
Number of subjects: 11
Study: 8063983

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2817305

Group type: EXPERIMENTAL
Intervention: Dp-treated group (unmodified Dp extract)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: mPEG-Dp group (mPEG modified Dp extract)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All groups (after 2 years)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Retrospective questionnaire data
Number of subjects: 46
Study: 1234486

Group type: EXPERIMENTAL
Intervention: Acebutolol (300 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Practolol (400 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 3
Study: 30859680

Group type: COMPARATOR
Intervention: Standard omeprazole doses
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Personalized therapy based on CYP2C19 polymorphism
Number of subjects: 133
Study: 28371078

Group type: EXPERIMENTAL
Intervention: 10% D/DC-containing cream
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20% D/DC-containing cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) scores for pruritus in D/DC-treated groups
Number of subjects: 50
Study: 26460279

Group type: EXPERIMENTAL
Intervention: Prasugrel (loading/maintenance dose: 20/3.75 mg)
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Clopidogrel (loading/maintenance dose: 300/75 mg)
Number of subjects: 1363
Study: 23181738

Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed once-a-day hypertension medications upon awakening
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Ingesting ≥1 medications at bedtime
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Asleep systolic BP mean <103 mm Hg
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Bedtime hypertension treatment
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Progressive reduction in asleep BP mean
Number of subjects: 2156
Study: 21823378

Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 58

Group type: COMPARATOR
Intervention: LMA
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison of SLIPA and LMA
Number of subjects: 58
Study: 17917685

Group type: EXPERIMENTAL
Intervention: Immediate Sequential Cataract Surgery (ISCS)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Delayed Sequential Cataract Surgery (DSCS)
Number of subjects: 220
Study: 16754269

Group type: EXPERIMENTAL
Intervention: Candesartan 8‐16 mg daily
Number of subjects: 4937

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4937
Study: 15816267

Group type: EXPERIMENTAL
Intervention: Carbohydrate test foods (bread, roti, rice) consumed by Type 2 diabetic patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy non-diabetic subjects
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients visiting either clinic
Number of subjects: 38
Study: 11571822

Group type: EXPERIMENTAL
Intervention: Active treatment (impulse magnetic-field therapy, 16 Hz, 5 microTs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 9784038

Group type: EXPERIMENTAL
Intervention: Oral Imedeen
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 8152361

Group type: EXPERIMENTAL
Intervention: Methods of rank order, category scaling, time tradeoff, and standard gamble
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nursing home residents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current health and severe constant pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dementia and coma
Number of subjects: 0
Study: 2578012

Group type: COMPARATOR
Intervention: Mantle irradiation (M)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Extended field mantle plus para‐aortic (M + PA) irradiation
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Sandwiched mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) X 3, M irradiation, MOPP X 3 protocol (3M)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Total/subtotal nodal irradiation (TNI/STNI)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: 3M
Number of subjects: 494

Group type: COMPARATOR
Intervention: TNI/STNI
Number of subjects: 494
Study: 28719008

Group type: EXPERIMENTAL
Intervention: Gemigliptin (50 mg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo transitioned to Linagliptin
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Gemigliptin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Linagliptin
Number of subjects: 132
Study: 27894327

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 (±1) °C for 48 hours
Number of subjects: 355

Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33 (±1) °C for 24 hours
Number of subjects: 355
Study: 24438386

Group type: EXPERIMENTAL
Intervention: Dynamic stretching routine (DS1; 6.7 ± 1.3 min)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dynamic stretching routine (DS2; 12.1 ± 1.6 min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control condition (CON; 5‐min jog + 12 min of resting)
Number of subjects: 26
Study: 22943969

Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 2 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 4 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 12 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unheated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 4 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg)
Number of subjects: 12
Study: 21095263

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus Simvastatin 20 mg daily
Number of subjects: 9438

Group type: COMPARATOR
Intervention: Simvastatin 20 mg daily
Number of subjects: 9438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9438
Study: 18692886

Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI (45 microg per dose)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Racemic albuterol HFA MDI (90 microg per dose)
Number of subjects: 49
Study: 15960560

Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Duloxetine (80-120 mg/day)
Number of subjects: 1466
Study: 12610044

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg o.d. for >26 weeks)
Number of subjects: 131
Study: 10515398

Group type: COMPARATOR
Intervention: Continuous training (C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interval training (I)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both training groups (C and I)
Number of subjects: 21
Study: 7669958

Group type: EXPERIMENTAL
Intervention: Low loading dose of milrinone (20 micrograms/kg during 15 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High loading dose of milrinone (40 micrograms/kg during 15 minutes)
Number of subjects: 20
Study: 2256645

Group type: EXPERIMENTAL
Intervention: Imocur
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 6770673

Group type: EXPERIMENTAL
Intervention: Cefaclor (40 mg/kg/day for 10 days to 3 weeks)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Amoxicillin trihydrate (40 mg/kg/day for 10 days to 3 weeks)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Cefaclor (20 mg/kg/day for 10 days)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Penicillin V potassium (20 mg/kg/day for 10 days)
Number of subjects: 218
Study: 31018684

Group type: EXPERIMENTAL
Intervention: Exercise plus usual care (n = 21)
Number of subjects: 41
Study: 28240983

Group type: EXPERIMENTAL
Intervention: Digits-in-noise (DIN) test administered via personal computer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hearing Handicap Inventory for Adults (HHIA) questionnaire
Number of subjects: 40
Study: 28391665

Group type: EXPERIMENTAL
Intervention: Whitening dentifrice with sodium fluoride and sodium hexametaphosphate (SHMP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dental prophylaxis
Number of subjects: 50
Study: 24616337

Group type: EXPERIMENTAL
Intervention: EUROACTION PLUS (EA+)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 696
Study: 23094264

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Colgate Motion)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B Advantage)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B CrossAction)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B ShinyClean)
Number of subjects: 40
Study: 19823185

Group type: EXPERIMENTAL
Intervention: 1500 mg dairy and non-dairy calcium
Number of subjects: 34

Group type: COMPARATOR
Intervention: 500 mg dairy and non-dairy calcium
Number of subjects: 34
Study: 18171957

Group type: COMPARATOR
Intervention: Eccentric loading (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shock wave therapy (Group 2)
Number of subjects: 50
Study: 16120776

Group type: EXPERIMENTAL
Intervention: Placebo with expected analgesic properties
Number of subjects: 0
Study: 12590855

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, 7-day regimen)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg, 10-day regimen)
Number of subjects: 452
Study: 10232720

Group type: EXPERIMENTAL
Intervention: Ondansetron 100 microg x kg(‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 8934467

Group type: EXPERIMENTAL
Intervention: 3D‐CTA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: STA‐MCA anastomosis
Number of subjects: 52
Study: 8452170

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 7 days
Number of subjects: 625

Group type: COMPARATOR
Intervention: Amoxicillin 500 mg every 8 hours for 7 days
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 625

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 625
Study: 3540918

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) administered twice daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tripotassium dicitrato bismuthate (TDB) administered four times daily
Number of subjects: 53
Study: 29917255

Group type: EXPERIMENTAL
Intervention: Avatar-based heart attack education application
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 27693654

Group type: EXPERIMENTAL
Intervention: Tobacco Heating System 2.2 (THS 2.2)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional Cigarettes (CCs)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Smoking Abstinence
Number of subjects: 160
Study: 23749481

Group type: EXPERIMENTAL
Intervention: Qigong exercise (18 Forms Tai Chi Internal Qigong for approximately 6 minutes)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (resting for similar duration in a sitting position)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 23
Study: 25092441

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22024905

Group type: EXPERIMENTAL
Intervention: High-dose supervised strengthening exercise with spinal manipulation (ET + SMT)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: High-dose supervised strengthening exercise (ET)
Number of subjects: 270
Study: 19606689

Group type: EXPERIMENTAL
Intervention: Johrei treatment (18 sessions over 6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 39
Study: 17595258

Group type: EXPERIMENTAL
Intervention: Recombinant GH (50 mug/kg.d; n = 45)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No treatment (n = 43)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 88